Literature DB >> 12214277

Serial analysis of gene expression in normal p53 null mammary epithelium.

C Marcelo Aldaz1, Yuhui Hu, Rachael Daniel, Sally Gaddis, Frances Kittrell, Daniel Medina.   

Abstract

Much evidence has accumulated implicating the p53 gene as of importance in breast carcinogenesis. However, much still remains to be uncovered on the specific downstream pathways influenced by this important activator/repressor of transcription. This study investigated the effects of a p53 null genotype on the transcriptome of 'normal' mouse mammary epithelium using a unique in vivo model of preneoplastic transformation. We used SAGE for the comparative analysis of p53 wild type (wt) and null mammary epithelium unexposed and exposed to hormonal stimulation. Analysis of the hormone exposed samples provided a comprehensive view of the dramatic changes in gene expression as consequence of the functional differentiation of the mammary epithelium in an in vivo system. We detected the dysregulation in p53(null) epithelium of <1% of the transcriptome. Changes in expression affected not only known p53 target genes, but also several unexpected genes such as Expi (Wdnm1), Cyp1b1, Gelsolin, Ramp2 and class I MHC genes. The dysregulation of specific genes and their potential use as preneoplastic markers was further validated using an independent model of premalignant mammary outgrowth lines. This is the first study to examine the transcriptome of very early stages of preneoplastic progression in an in vivo model that mimics human breast cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12214277     DOI: 10.1038/sj.onc.1205816

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  13 in total

1.  Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells.

Authors:  Jason I Herschkowitz; Wei Zhao; Mei Zhang; Jerry Usary; George Murrow; David Edwards; Jana Knezevic; Stephanie B Greene; David Darr; Melissa A Troester; Susan G Hilsenbeck; Daniel Medina; Charles M Perou; Jeffrey M Rosen
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-01       Impact factor: 11.205

2.  Thermal enhancement with optically activated gold nanoshells sensitizes breast cancer stem cells to radiation therapy.

Authors:  Rachel L Atkinson; Mei Zhang; Parmeswaran Diagaradjane; Sirisha Peddibhotla; Alejandro Contreras; Susan G Hilsenbeck; Wendy A Woodward; Sunil Krishnan; Jenny C Chang; Jeffrey M Rosen
Journal:  Sci Transl Med       Date:  2010-10-27       Impact factor: 17.956

3.  From mice to humans: identification of commonly deregulated genes in mammary cancer via comparative SAGE studies.

Authors:  Yuhui Hu; Hongxia Sun; Jeffrey Drake; Frances Kittrell; Martin C Abba; Li Deng; Sally Gaddis; Aysegul Sahin; Keith Baggerly; Daniel Medina; C Marcelo Aldaz
Journal:  Cancer Res       Date:  2004-11-01       Impact factor: 12.701

4.  Identification of modulated genes by three classes of chemopreventive agents at preneoplastic stages in a p53-null mouse mammary tumor model.

Authors:  Martín C Abba; Yuhui Hu; Carla C Levy; Sally Gaddis; Frances S Kittrell; Jamal Hill; Reid P Bissonnette; Powel H Brown; Daniel Medina; C Marcelo Aldaz
Journal:  Cancer Prev Res (Phila)       Date:  2009-01-27

5.  Identification of novel amplification gene targets in mouse and human breast cancer at a syntenic cluster mapping to mouse ch8A1 and human ch13q34.

Authors:  Martin C Abba; Victoria T Fabris; Yuhui Hu; Frances S Kittrell; Wei-Wen Cai; Lawrence A Donehower; Aysegul Sahin; Daniel Medina; C Marcelo Aldaz
Journal:  Cancer Res       Date:  2007-05-01       Impact factor: 12.701

6.  ESR1 promoter hypermethylation does not predict atypia in RPFNA nor persistent atypia after 12 months tamoxifen chemoprevention.

Authors:  Joseph C Baker; Julie H Ostrander; Siya Lem; Gloria Broadwater; Gregory R Bean; Nicholas C D'Amato; Vanessa K Goldenberg; Craig Rowell; Catherine Ibarra-Drendall; Tracey Grant; Patrick G Pilie; Shauna N Vasilatos; Michelle M Troch; Victoria Scott; Lee G Wilke; Carolyn Paisie; Sarah M Rabiner; Alejandro Torres-Hernandez; Carola M Zalles; Victoria L Seewaldt
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-08       Impact factor: 4.254

7.  Growth-inhibitory and tumor- suppressive functions of p53 depend on its repression of CD44 expression.

Authors:  Samuel Godar; Tan A Ince; George W Bell; David Feldser; Joana Liu Donaher; Jonas Bergh; Anne Liu; Kevin Miu; Randolph S Watnick; Ferenc Reinhardt; Sandra S McAllister; Tyler Jacks; Robert A Weinberg
Journal:  Cell       Date:  2008-07-11       Impact factor: 41.582

8.  Profile of estrogen-responsive genes in an estrogen-specific mammary gland outgrowth model.

Authors:  Bonnie J Deroo; Sylvia C Hewitt; Jennifer B Collins; Sherry F Grissom; Katherine J Hamilton; Kenneth S Korach
Journal:  Mol Reprod Dev       Date:  2009-08       Impact factor: 2.609

9.  Identification of tumor-initiating cells in a p53-null mouse model of breast cancer.

Authors:  Mei Zhang; Fariba Behbod; Rachel L Atkinson; Melissa D Landis; Frances Kittrell; David Edwards; Daniel Medina; Anna Tsimelzon; Susan Hilsenbeck; Jeffrey E Green; Aleksandra M Michalowska; Jeffrey M Rosen
Journal:  Cancer Res       Date:  2008-06-15       Impact factor: 12.701

10.  p53Ψ is a transcriptionally inactive p53 isoform able to reprogram cells toward a metastatic-like state.

Authors:  Serif Senturk; Zhan Yao; Matthew Camiolo; Brendon Stiles; Trushar Rathod; Alice M Walsh; Alice Nemajerova; Matthew J Lazzara; Nasser K Altorki; Adrian Krainer; Ute M Moll; Scott W Lowe; Luca Cartegni; Raffaella Sordella
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-29       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.